H.C. Wainwright analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage